Advertisement

Topics

Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults

22:11 EST 8 Nov 2017 | Drugs.com

BERKELEY, CA -- (Marketwired) -- November 9, 2017 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for...

Original Article: Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults

NEXT ARTICLE

More From BioPortfolio on "Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...